We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

GenomOncology Collaborates with Roswell Park Cancer Institute

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

GenomOncology has announced a collaboration with Roswell Park Cancer Institute (RPCI) to develop an informatics solution that enables the association of Next Generation Sequencing results with knowledge resources to define actionable mutations.

“The challenges of translating the vast amounts of data from next-generation sequencing into a resource that can be easily and effectively incorporated into clinical and research programs are significant,” said Dr. Carl Morrison, Executive Director of the Center for Personalized Medicine at Roswell Park.

Dr. Morrison continued, “We need next-generation tools that will help us to deliver the best and most appropriate therapies to our patients through a streamlined process.”

GenomOncology and RPCI are working together to develop a software platform that integrates laboratory information management systems, electronic health records, information technology and bioinformatics and that provides a workflow enabling genomic analysts and pathologists to create actionable reports.

GenomOncology will be demonstrating this software platform at two upcoming conferences, Advances in Genome Biology & Technology (AGBT) in February and United States & Canadian Academy of Pathology (USCAP) in March.